Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

Cancer

Volumn 116, Issue 12, 2010, Pages 3054-3060

  Kushner, Brian H ^a   Kramer, Kim ^a   Modak, Shakeel ^a   Qin, Li Xuan ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemoresistance; Cyclophosphamide; Neuroblastoma; Salvage therapy; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IRINOTECAN; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CHILD; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROBLASTOMA; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; TREATMENT RESPONSE; TYPHLITIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; SALVAGE THERAPY; TOPOTECAN; VINCRISTINE;

EID: 77953965562     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25232     Document Type: Article

References (36)

1. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomized controlled trial. Lancet Oncol. 2005;6:649-658. (Pubitemid 41222755)
2. Pearson ADJ, Pinkerton CR, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial. Lancet Oncol. 2008;9:247-256. (Pubitemid 351722944)
3. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469. (Pubitemid 32730082)
4. Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488-2494. (Pubitemid 37466665)
5. Donfrancesco A, Jenkner A, Castellano A, et al. Ifosfamide/carboplatin/ etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over 1 year of age. Acta Paediatr Suppl. 2004;445:6-11.
6. Simon T, Langler A, Berthold F, Klingebiel T, Hero B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol. 2007;29:101-106. (Pubitemid 46213856)
7. Simon T, Langler A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma: results of a phase-II trial. J Cancer Res Clin Oncol. 2007;133:653-661. (Pubitemid 47077057)
8. Parks JR, Stewart CF, London WB, et al. Targeted topotecan during induction therapy of high risk neuroblastoma: a COG pilot study [abstract]. Proc Am Soc Clin Oncol. 2006; 24. Abstract 9013.
9. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000;35:468-474.
10. Jenkner A, Donfrancesco A, Ilari I, et al. Topotecan and high dose cyclophosphamide followed by ifosfamide, carboplatin and etoposide in newly diagnosed high risk neuroblastoma. Adv Neuroblastoma Res. 2006;126.
11. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999;5:3617-3631.
12. Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res. 2004;10:84-87. (Pubitemid 38114165)
13. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: the Italian experience. Cancer. 2006;106:1409-1417.
14. Esiashvili N, Goodman M, Ward K, Marcus RB, Johnstone PAS. Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2007;49:41-46. (Pubitemid 46847066)
15. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
16. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888-4892. (Pubitemid 46638612)
17. Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. Proc Am Soc Clin Oncol. 2007;25:527s.
18. Castleberry RP, Cantgor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994;12:1616-1620.
19. Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a Pediatric Oncology Group study. J Clin Oncol. 2004;22:4119-4126. (Pubitemid 41185181)
20. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;18:2891-2896. (Pubitemid 46630591)
21. Kushner BH, Yeh SDJ, Kramer K, Larson SM, Modak S, Cheung NK. Impact of MIBG scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082-1086. (Pubitemid 46594137)
22. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041-1046.
23. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001;28:551-556. (Pubitemid 32976354)
24. Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:601-605. (Pubitemid 36959419)
25. Kushner BH, Kramer K, Modak S, et al. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transplant. 2006;37:271-276.
26. Pommier Y, Gupta M, Valenti M, et al. Cellular resistance to camptothecins. Ann N Y Acad Sci. 1996;803:60-73.
27. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a 5-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1996;18:352-361.
28. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20:315-318. (Pubitemid 28483337)
29. Saylors RL III, Stewart CF, Zamboni WE, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:945-952. (Pubitemid 28108727)
30. Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol. 1996;37:195-202.
31. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996;88:734-741. (Pubitemid 26195021)
32. Teicher BA, Cucchi CA, Lee JB, et al. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res. 1986;46:4379-4388.
33. Kushner BH, Gulati SC, O'Reilly RJ, Heller G, Cheung NK. Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. Med Pediatr Oncol. 1990;18:454-458.
34. Brodsky RA, Petri M, Smith BD, et al. Immunoablative highdose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998;129:1031-1035. (Pubitemid 29005827)
35. Murren JR, Anderson S, Fedele J, et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol. 1997;15:148-157. (Pubitemid 27021525)
36. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer. 2007;48:430-434. (Pubitemid 46340109)